Changes in Body Weight and Metabolism Were Similarly Slight for LA-CAB/RPV vs. BIC/FTC/TAF

Switching to long-acting cabotegravir and rilpirivine compared with continuing oral bictegravir/emtricitabine/tenofovir alafenamide presented no clinically relevant differences in morphologic or metabolic parameters at 12 months.

Despite the remarkable virologic success of current antiretroviral therapy (ART) regimens, concerns remain about the metabolic effects of each component drug. In the SOLAR trial, investigators reported comparable virologic efficacy when persons living with HIV (PLWH) who achieved suppression on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) were switched to long-acting cabotegravir and rilpirivine (LA-CAB/RPV) dosed every 2 months. Now, metabolic and morphologic changes after 12 months on LA-CAB/RPV or BIC/FTC/TAF were compared among the participants (none of whom were taking lipid-modifying drugs).

Median changes from baseline in body weight were −0.4 kg (LA-CAB/RPV) and +0.1 kg (BIC/FTC/TAF) and in waist circumference were +…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Changes in Body Weight and Metabolism Were Similarly Slight for LA-CAB/RPV vs. BIC/FTC/TAF

Topics

Reviewing Author